Do analysts rate MOR or GLAS?

Glass House Brands has a consensus price target of $17.00, indicating a potential upside of 70.36%. Given Glass House Brands' stronger consensus rating and higher possible upside, analysts plainly believe Glass House Brands is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Glass House Brands 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has better earnings and valuation, MOR or GLAS?

Glass House Brands has lower revenue, but higher earnings than MorphoSys. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A Glass House Brands N/A N/A N/A N/A N/A

Which has stronger earnings & valuation, GLAS or TRVI?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glass House Brands N/A N/A N/A N/A N/A Trevi Therapeutics N/A N/A -$42.76M -$0.34 N/A

Is GLAS or TRVI more profitable?

Glass House Brands' return on equity of 0.00% beat Trevi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Glass House Brands N/A N/A N/A Trevi Therapeutics N/A -23.59% -22.64%

Does the media prefer GLAS or TRVI?

In the previous week, Trevi Therapeutics had 8 more articles in the media than Glass House Brands. MarketBeat recorded 11 mentions for Trevi Therapeutics and 3 mentions for Glass House Brands. Trevi Therapeutics' average media sentiment score of 0.47 beat Glass House Brands' score of -0.33 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glass House Brands 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trevi Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, GLAS or ATAI?

Glass House Brands has higher earnings, but lower revenue than Atai Beckley. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glass House Brands N/A N/A N/A N/A N/A Atai Beckley $4.09M 649.02 -$660.05M -$2.23 N/A

Does the media refer more to GLAS or ATAI?

In the previous week, Atai Beckley had 1 more articles in the media than Glass House Brands. MarketBeat recorded 4 mentions for Atai Beckley and 3 mentions for Glass House Brands. Atai Beckley's average media sentiment score of 1.37 beat Glass House Brands' score of -0.33 indicating that Atai Beckley is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glass House Brands 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, TARS or GLAS?

Glass House Brands has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tarsus Pharmaceuticals $451.36M 6.75 -$66.42M -$1.09 N/A Glass House Brands N/A N/A N/A N/A N/A

Does the media prefer TARS or GLAS?

In the previous week, Tarsus Pharmaceuticals had 24 more articles in the media than Glass House Brands. MarketBeat recorded 27 mentions for Tarsus Pharmaceuticals and 3 mentions for Glass House Brands. Tarsus Pharmaceuticals' average media sentiment score of -0.03 beat Glass House Brands' score of -0.33 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Glass House Brands 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, GLAS or SUPN?

Glass House Brands has higher earnings, but lower revenue than Supernus Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glass House Brands N/A N/A N/A N/A N/A Supernus Pharmaceuticals $718.95M 3.79 -$38.55M -$1.92 N/A

Does the media favor GLAS or SUPN?

In the previous week, Supernus Pharmaceuticals had 5 more articles in the media than Glass House Brands. MarketBeat recorded 8 mentions for Supernus Pharmaceuticals and 3 mentions for Glass House Brands. Supernus Pharmaceuticals' average media sentiment score of 0.70 beat Glass House Brands' score of -0.33 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glass House Brands 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Supernus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Glass House Brands (GLAS) Competitors

$9.98 -0.03 (-0.31%)

Closing price 08/11/2026 03:59 PM Eastern

Extended Trading

$10.00 +0.02 (+0.22%)

As of 04:09 AM Eastern

Compare

GLAS vs. MOR, TRVI, ATAI, TARS, and SUPN

Should you buy Glass House Brands stock or one of its competitors? Glass House Brands's main competitors and comparable companies include MorphoSys (MOR), Trevi Therapeutics (TRVI), Atai Beckley (ATAI), Tarsus Pharmaceuticals (TARS), and Supernus Pharmaceuticals (SUPN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Glass House Brands compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Glass House Brands (NYSE:GLAS) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

18.4% of MorphoSys shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Glass House Brands has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Glass House Brands' return on equity of 0.00% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Glass House Brands	N/A	N/A	N/A

Glass House Brands has a consensus price target of $17.00, indicating a potential upside of 70.36%. Given Glass House Brands' stronger consensus rating and higher possible upside, analysts plainly believe Glass House Brands is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Glass House Brands	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Glass House Brands has lower revenue, but higher earnings than MorphoSys.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Glass House Brands	N/A	N/A	N/A	N/A	N/A

In the previous week, Glass House Brands had 3 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for Glass House Brands and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.00 beat Glass House Brands' score of -0.33 indicating that MorphoSys is being referred to more favorably in the media.

Company	Overall Sentiment
MorphoSys	Neutral
Glass House Brands	Neutral

Summary

Glass House Brands beats MorphoSys on 8 of the 12 factors compared between the two stocks.

How does Glass House Brands compare to Trevi Therapeutics?

Glass House Brands (NYSE:GLAS) and Trevi Therapeutics (NASDAQ:TRVI) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

95.8% of Trevi Therapeutics shares are owned by institutional investors. 15.4% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Glass House Brands' return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glass House Brands	N/A	N/A	N/A
Trevi Therapeutics	N/A	-23.59%	-22.64%

Glass House Brands presently has a consensus price target of $17.00, suggesting a potential upside of 70.36%. Trevi Therapeutics has a consensus price target of $26.75, suggesting a potential upside of 50.28%. Given Glass House Brands' higher possible upside, equities research analysts clearly believe Glass House Brands is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glass House Brands	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glass House Brands	N/A	N/A	N/A	N/A	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A

In the previous week, Trevi Therapeutics had 8 more articles in the media than Glass House Brands. MarketBeat recorded 11 mentions for Trevi Therapeutics and 3 mentions for Glass House Brands. Trevi Therapeutics' average media sentiment score of 0.47 beat Glass House Brands' score of -0.33 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glass House Brands	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trevi Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Trevi Therapeutics beats Glass House Brands on 7 of the 10 factors compared between the two stocks.

How does Glass House Brands compare to Atai Beckley?

Glass House Brands (NYSE:GLAS) and Atai Beckley (NASDAQ:ATAI) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

In the previous week, Atai Beckley had 1 more articles in the media than Glass House Brands. MarketBeat recorded 4 mentions for Atai Beckley and 3 mentions for Glass House Brands. Atai Beckley's average media sentiment score of 1.37 beat Glass House Brands' score of -0.33 indicating that Atai Beckley is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glass House Brands	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

28.4% of Atai Beckley shares are owned by institutional investors. 19.8% of Atai Beckley shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Glass House Brands has higher earnings, but lower revenue than Atai Beckley.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glass House Brands	N/A	N/A	N/A	N/A	N/A
Atai Beckley	$4.09M	649.02	-$660.05M	-$2.23	N/A

Glass House Brands has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Glass House Brands' return on equity of 0.00% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glass House Brands	N/A	N/A	N/A
Atai Beckley	-19,019.44%	-89.79%	-63.58%

Glass House Brands currently has a consensus target price of $17.00, indicating a potential upside of 70.36%. Atai Beckley has a consensus target price of $11.06, indicating a potential upside of 53.35%. Given Glass House Brands' stronger consensus rating and higher possible upside, analysts plainly believe Glass House Brands is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glass House Brands	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Atai Beckley	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.27

Summary

Atai Beckley beats Glass House Brands on 6 of the 11 factors compared between the two stocks.

How does Glass House Brands compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Glass House Brands (NYSE:GLAS) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

In the previous week, Tarsus Pharmaceuticals had 24 more articles in the media than Glass House Brands. MarketBeat recorded 27 mentions for Tarsus Pharmaceuticals and 3 mentions for Glass House Brands. Tarsus Pharmaceuticals' average media sentiment score of -0.03 beat Glass House Brands' score of -0.33 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Glass House Brands	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tarsus Pharmaceuticals presently has a consensus target price of $90.17, indicating a potential upside of 29.81%. Glass House Brands has a consensus target price of $17.00, indicating a potential upside of 70.36%. Given Glass House Brands' higher possible upside, analysts plainly believe Glass House Brands is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Glass House Brands	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Glass House Brands has lower revenue, but higher earnings than Tarsus Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	6.75	-$66.42M	-$1.09	N/A
Glass House Brands	N/A	N/A	N/A	N/A	N/A

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Glass House Brands has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Glass House Brands' return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Glass House Brands	N/A	N/A	N/A

Summary

Tarsus Pharmaceuticals beats Glass House Brands on 8 of the 12 factors compared between the two stocks.

How does Glass House Brands compare to Supernus Pharmaceuticals?

Glass House Brands (NYSE:GLAS) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Glass House Brands has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -13.23%. Supernus Pharmaceuticals' return on equity of 11.13% beat Glass House Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glass House Brands	N/A	N/A	N/A
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

Glass House Brands has higher earnings, but lower revenue than Supernus Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glass House Brands	N/A	N/A	N/A	N/A	N/A
Supernus Pharmaceuticals	$718.95M	3.79	-$38.55M	-$1.92	N/A

In the previous week, Supernus Pharmaceuticals had 5 more articles in the media than Glass House Brands. MarketBeat recorded 8 mentions for Supernus Pharmaceuticals and 3 mentions for Glass House Brands. Supernus Pharmaceuticals' average media sentiment score of 0.70 beat Glass House Brands' score of -0.33 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glass House Brands	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Supernus Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Glass House Brands currently has a consensus target price of $17.00, indicating a potential upside of 70.36%. Supernus Pharmaceuticals has a consensus target price of $62.83, indicating a potential upside of 34.03%. Given Glass House Brands' higher probable upside, analysts clearly believe Glass House Brands is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glass House Brands	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Supernus Pharmaceuticals beats Glass House Brands on 7 of the 9 factors compared between the two stocks.

Get Glass House Brands News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLAS vs. The Competition

Export

Metric	Glass House Brands	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$803.52M	$12.02B	$7.08B	$24.25B
Dividend Yield	N/A	2.69%	2.57%	3.70%
P/E Ratio	N/A	783.52	268.39	30.36
Price / Sales	N/A	750.79	559.59	68.52
Price / Cash	N/A	70.00	72.26	33.15
Price / Book	N/A	10.56	13.21	6.54
Net Income	N/A	$2.78B	$3.44B	$1.06B
7 Day Performance	7.43%	0.51%	2.07%	0.35%
1 Month Performance	-14.50%	-1.50%	-0.26%	2.41%
1 Year Performance	N/A	165.79%	70.30%	18.19%

Glass House Brands Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLAS Glass House Brands	3.3433 of 5 stars	$9.98 -0.3%	$17.00 +70.4%	N/A	$803.52M	N/A	N/A	N/A	Short Interest Increase
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
TRVI Trevi Therapeutics	2.8201 of 5 stars	$18.65 -0.5%	$24.91 +33.6%	+143.2%	$2.66B	N/A	N/A	20	Earnings Report
ATAI Atai Beckley	3.9738 of 5 stars	$7.22 +0.6%	$11.06 +53.1%	+82.1%	$2.64B	$4.09M	N/A	80	Positive News Earnings Report Short Interest Decrease
TARS Tarsus Pharmaceuticals	3.0168 of 5 stars	$61.29 +0.3%	$90.17 +47.1%	+38.7%	$2.64B	$535.08M	N/A	50	Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GLAS) was last updated on 8/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Glass House Brands (GLAS) Competitors

GLAS vs. MOR, TRVI, ATAI, TARS, and SUPN

How does Glass House Brands compare to MorphoSys?

Summary

How does Glass House Brands compare to Trevi Therapeutics?

Summary

How does Glass House Brands compare to Atai Beckley?

Summary

How does Glass House Brands compare to Tarsus Pharmaceuticals?

Summary

How does Glass House Brands compare to Supernus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLAS vs. The Competition

Glass House Brands Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Glass House Brands (GLAS) Competitors

GLAS vs. MOR, TRVI, ATAI, TARS, and SUPN

How does Glass House Brands compare to MorphoSys?

Do institutionals & insiders hold more shares of MOR or GLAS?

Is MOR or GLAS more profitable?

Do analysts rate MOR or GLAS?

Which has better earnings and valuation, MOR or GLAS?

Does the media refer more to MOR or GLAS?

Summary

How does Glass House Brands compare to Trevi Therapeutics?

Do institutionals and insiders have more ownership in GLAS or TRVI?

Is GLAS or TRVI more profitable?

Do analysts prefer GLAS or TRVI?

Which has stronger earnings & valuation, GLAS or TRVI?

Does the media prefer GLAS or TRVI?

Summary

How does Glass House Brands compare to Atai Beckley?

Does the media refer more to GLAS or ATAI?

Do institutionals & insiders believe in GLAS or ATAI?

Which has higher earnings and valuation, GLAS or ATAI?

Is GLAS or ATAI more profitable?

Do analysts rate GLAS or ATAI?

Summary

How does Glass House Brands compare to Tarsus Pharmaceuticals?

Does the media prefer TARS or GLAS?

Do analysts prefer TARS or GLAS?

Which has better earnings & valuation, TARS or GLAS?

Do institutionals and insiders hold more shares of TARS or GLAS?

Is TARS or GLAS more profitable?

Summary

How does Glass House Brands compare to Supernus Pharmaceuticals?

Is GLAS or SUPN more profitable?

Which has preferable earnings and valuation, GLAS or SUPN?

Does the media favor GLAS or SUPN?

Do analysts prefer GLAS or SUPN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLAS vs. The Competition

Glass House Brands Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools